Get the Stockscreener App
9.49
12.13%
-1.31
After Hours:
9.26
-0.23
-2.42%
Conexeu Sciences Inc stock is traded at $9.49, with a volume of 334.18K.
It is down -12.13% in the last 24 hours and down -37.75% over the past month.
Conexeu Sciences Inc is an early-stage medical technology company. The company develops and supplies collagen-based technologies that helps doctors and patients regenerate tissue naturally, safely, and effectively. The company is focused on developing regenerative biomaterials that address relative needs in wound care, dentistry, and aesthetics. The company seek to provide physicians with device-based solutions that improve healing, restore soft tissue, and enhance patient outcomes across multiple clinical settings. The company focuses durable, and growing addressable markets in regenerative aesthetics, wound care, 3D-printed tissue structures, veterinary wound repair, and dental soft-tissue regeneration.
See More
Previous Close:
$10.80
Open:
$11.11
24h Volume:
334.18K
Relative Volume:
8.66
Market Cap:
$253.94M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-13.10%
1M Performance:
-37.75%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$9.25
$11.51
1-Week Range:
$9.25
$11.51
52-Week Range:
$9.25
$18.79
Conexeu Sciences Inc Stock (CNXU) Company Profile
Name
Conexeu Sciences Inc
Sector
Industry
Phone
604-315-4722
Address
50 WEST LIBERTY STREET, SUITE 880, RENO
Compare CNXU vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNXU
Conexeu Sciences Inc
|
9.49 | 288.99M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Conexeu Sciences Inc Stock (CNXU) Latest News
Conex Completes 12-Month P.R.O.O.F Preclinical Study, Targets Q1 2027 510(k) for Wound Care - TradingView
[8-K] Conexeu Sciences Inc. Reports Material Event - Stock Titan
A $190 Billion Weight-Loss Boom Exposed a Tissue-Restoration Gap, and One Nasdaq Company Is Moving to Fill It - PR Newswire
Top Conexeu Sciences (CNXU) Competitors 2026 - MarketBeat
Conexeu Sciences (CNXU) Insider Trading Activity 2026 - MarketBeat
Enterprise value to EBITDA forward of Conexeu Sciences Inc. – NASDAQ:CNXU - TradingView
Conexeu Sciences (CNXU) Earnings Date and Reports 2026 - MarketBeat
Conexeu Sciences Inc. Common Stock (NASDAQ: CNXU) Stock Price, News & Analysis - Kalkine
Price to book forward of Conexeu Sciences Inc. – NASDAQ:CNXU - TradingView
Enterprise value to revenue forward of Conexeu Sciences Inc. – NASDAQ:CNXU - TradingView
Price to sales forward of Conexeu Sciences Inc. – NASDAQ:CNXU - TradingView
A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity - Investing News Network
CNXU News Today | Why did Conexeu Sciences stock go up today? - MarketBeat
Conexeu Sciences (CNXU) Stock Forecast and Price Target 2026 - MarketBeat
Conexeu Sciences : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
50,000 options reported by Conexeu Sciences (CNXU) director - Stock Titan
Conexeu Sciences (CNXU) 10K Form and Latest SEC Filings 2026 - MarketBeat
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
CNXU Forecast — Price Target — Prediction for 2027 - TradingView
Conexeu Sciences, Inc. Actuals & Estimates (NASDAQ:CNXU) - TradingView
Conexeu Sciences (CNXU) Stock Trends and Sentiment 2026 - MarketBeat
Conexeu Sciences opens R&D facility in Vancouver - Investing.com
The Aesthetics Giants Just Confirmed "Ozempic Face" Is Realand a Newly Public Regenerative Player Wants to Compete for It - Investing News Network
Conexeu Sciences opens R&D facility in Vancouver By Investing.com - Investing.com Australia
Conexeu Sciences Opens Vancouver R&D Facility to Advance Regenerative Tissue Platform - The Manila Times
Conexeu Launches R&D Facility at M4 to Innovate Wound Healing Tech - techcouver.com
Conexeu Sciences Inc.: Target Price Consensus and Analysts Recommendations | CNXU | US20715F1003 - marketscreener.com
Conexeu Sciences (CNXU) director holds 50K options at $2.30, 2031 expiry - Stock Titan
Conexeu Sciences aims for FDA clearance by 2027 with a promising regenerative medicine product. - Pluang
Conexeu Sciences: Hanging On The FDA 510(k) Pathway Submission - Seeking Alpha
Insider Stock Purchases: June 24, 2026 - Moomoo
TradingKey - TradingKey
Conexeu Sciences Ord Shs (CNXU) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Conexeu Sciences Ord Shs (CNXU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Conexeu Sciences Ord Shs (CNXU) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Conexeu Sciences Ord Shs (CNXU) Valuation: PE, PB & Fair Value Analysis - TradingKey
CNXU|Conexeu Sciences Ord Shs|Price:10.860|Chg%:0.60 - TradingKey
CNXU|Conexeu Sciences Ord Shs|Price:10.360|Chg%:-0.33 - TradingKey
Conexeu Sciences Ord Shs (CNXU) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Conexeu Sciences Ord Shs (CNXU) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Conexeu Sciences Ord Shs (CNXU) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CNXU|Conexeu Sciences Ord Shs|Price:10.820|Chg%:0.27 - TradingKey
[Form 3] Conexeu Sciences Inc. Initial Statement of Beneficial Ownership - Stock Titan
Insider at Conexeu Sciences (CNXU) adds common stock and warrants - Stock Titan
Homegrown biotech firm launches new R&D lab space in Vancouver - Business in Vancouver
This Credo Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Sahm
H.C. Wainwright Initiates Conexeu Sciences(CNXU.US) With Buy Rating, Announces Target Price $20 - Moomoo
Conexeu Sciences (CNXU) 10% owner exercises 250K warrants via N3GU - Stock Titan
Conexeu Sciences initiated with a Buy at H.C. Wainwright - TipRanks
CNXU Initiates Coverage by HC Wainwright & Co. -- Rating Set to Buy - GuruFocus
Conexeu Sciences stock initiated at buy by H.C. Wainwright, $20 target - Investing.com South Africa
Conexeu Sciences Inc Stock (CNXU) Financials Data
There is no financial data for Conexeu Sciences Inc (CNXU). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.17%
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):